Form 4 for IDXX Idexx Laboratories
Accepted 2022-02-16 00:00:00 ET · period of report 2022-02-14 · accession 0001567619-22-004783 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-02-16 | 2022-02-14 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | $0.00 | +3,063 | 49.9K | +7% | $0 |
| D | 2022-02-16 | 2022-02-14 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | F - Tax | $505.53 | -1,423 | 51.1K | -3% | -$719.4K |
| DM | 2022-02-16 | 2022-02-14 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | — | -3,063 | 13.0K | -19% | — |
| DM | 2022-02-16 | 2022-02-14 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | A - Grant | — | +39.0K | 22.4K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-14 | M | A | 505 | $0.00 | 50,409.64 | D | — | — | |
| 2 | Common | Common Stock | 2022-02-14 | M | A | 435 | $0.00 | 50,844.64 | D | — | — | |
| 3 | Common | Common Stock | 2022-02-14 | F | D | 1,423 | $505.53 | 51,085.64 | D | — | — | |
| 4 | Common | Common Stock | 2022-02-14 | M | A | 974 | $0.00 | 51,818.64 | D | — | — | |
| 5 | Common | Common Stock | 2022-02-14 | M | A | 690 | $0.00 | 52,508.64 | D | — | — | |
| 6 | Common | Common Stock | 2022-02-14 | M | A | 459 | $0.00 | 49,904.64 | D | — | — | (F1) Includes a total of 19 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2021 and December 31, 2021. |
| 7 | Derivative | Restricted Stock Unit | 2022-02-14 | M | D | 974 | — | 11,065 | D | — · — to — | 974 Common Stock | (F11) Not applicable. (F9) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. |
| 8 | Derivative | Restricted Stock Unit | 2022-02-14 | M | D | 690 | — | 10,375 | D | — · — to — | 690 Common Stock | (F11) Not applicable. (F10) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. |
| 9 | Derivative | Restricted Stock Unit | 2022-02-14 | M | D | 435 | — | 12,039 | D | — · — to — | 435 Common Stock | (F11) Not applicable. (F8) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. |
| 10 | Derivative | Restricted Stock Unit | 2022-02-14 | M | D | 505 | — | 12,474 | D | — · — to — | 505 Common Stock | (F11) Not applicable. (F7) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. |
| 11 | Derivative | Restricted Stock Unit | 2022-02-14 | M | D | 459 | — | 12,979 | D | — · — to — | 459 Common Stock | (F11) Not applicable. (F6) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. |
| 12 | Derivative | Restricted Stock Unit | 2022-02-14 | A | A | 3,833 | — | 13,438 | D | — · — to — | 3,833 Common Stock | (F11) Not applicable. (F5) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. |
| 13 | Derivative | Incentive Stock Option (right-to-buy) | 2022-02-14 | A | A | 197 | — | 197 | D | $505.53 · — to 2032-02-13 | 197 Common Stock | (F11) Not applicable. (F4) Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on the fourth anniversary of the date of grant. |
| 14 | Derivative | Premium Non-Qualified Stock Option (right-to-buy) | 2022-02-14 | A | A | 12,557 | — | 12,557 | D | $556.08 · — to 2032-02-13 | 12,557 Common Stock | (F11) Not applicable. (F3) Grant of option at a 110% premium to the closing price of Issuer common stock on the NASDAQ Global Select Market on February 14, 2022 to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023. |
| 15 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2022-02-14 | A | A | 22,366 | — | 22,366 | D | $505.53 · — to 2032-02-13 | 22,366 Common Stock | (F11) Not applicable. (F2) Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023. |